(Total Views: 408)
Posted On: 02/12/2018 7:07:34 PM
Post# of 15624
Re: freedomdreamer #12000
I took a look at CNBX and found they had traded for over $6 at one point, and are currently over $1, Institutions could certainly have gotten in, and I suppose they can stay in as long as their charter permits them to hold stocks they've lost on, in the belief that they'll rise again. I really know little about it and am not looking for a stock at that price to invest in.
I suspect that had we held the $3 price longer, we'd have some more institutional investors, but if we go over $5 they'll really jump in, provided they aren't restricted from investing in cannabis based stocks.
I believe this will happen in time, but we either must have product in the market, or a major partnership that really excites investors. I believe the biggest reason the company has been so quiet is the companies they may be speaking with. Of course those discussions fall under confidentiality agreements, but they certainly could have told us more about trials. They may have an agreement with companies they're speaking with not to divulge anything that isn't a material event. Things like trial design and initiation are only material events if someone pays when they occur.
To me, the trial I'd like to know more about is the one for fibromyalgia. I believe that it may be with people who have the disease, and while it's only Phase 1, I believe it could definitely demonstrate not only safety, but efficacy. I don't know that much about Israeli trials, but the next trial could potentially lead to approval there. If anyone knows how their FDA operates, please let me know. i know they want to comply with International protocols, but even here in the U.S. it's possible to do registrational Phase 2 Trials, so I believe the same should be true there, the question might be, how large might such a trial be, and how great a period would they want to see data for. I suspect it would be somewhat less rigorous than our FDA would demand.
Gary
I suspect that had we held the $3 price longer, we'd have some more institutional investors, but if we go over $5 they'll really jump in, provided they aren't restricted from investing in cannabis based stocks.
I believe this will happen in time, but we either must have product in the market, or a major partnership that really excites investors. I believe the biggest reason the company has been so quiet is the companies they may be speaking with. Of course those discussions fall under confidentiality agreements, but they certainly could have told us more about trials. They may have an agreement with companies they're speaking with not to divulge anything that isn't a material event. Things like trial design and initiation are only material events if someone pays when they occur.
To me, the trial I'd like to know more about is the one for fibromyalgia. I believe that it may be with people who have the disease, and while it's only Phase 1, I believe it could definitely demonstrate not only safety, but efficacy. I don't know that much about Israeli trials, but the next trial could potentially lead to approval there. If anyone knows how their FDA operates, please let me know. i know they want to comply with International protocols, but even here in the U.S. it's possible to do registrational Phase 2 Trials, so I believe the same should be true there, the question might be, how large might such a trial be, and how great a period would they want to see data for. I suspect it would be somewhat less rigorous than our FDA would demand.
Gary
(0)
(0)Scroll down for more posts ▼
